PALIPERIDONE (paliperidone) by Dr. Reddy's Laboratories is risperidone. Approved for schizophrenia () adults: efficacy was established in three 6-week trials, one maintenance trial, schizophrenia [see clinical studies ()] and 4 more indications. First approved in 2025.
Drug data last refreshed 1w ago
risperidone. The mechanism of action of paliperidone in schizophrenia is unclear. However, the drug's therapeutic effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2A ) receptor antagonism.
Worked on PALIPERIDONE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
A Study of Paliperidone Palmitate 6-Month Formulation
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities